Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Wayland Group Corp MRRCF

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic Cannabis
Wayland Group Corp, formerly Maricann Group Inc produces and sells medical marijuana. It is currently engaged in cultivation, extraction, analytics and production facilities to elevate offerings and prepare for growth into the adult-use cannabis market in Canada.


GREY:MRRCF - Post by User

Wayland Group Corp
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Pumperknicleon Mar 29, 2018 7:34am
56 Views
Post# 27800786

RE:Growing weed in Germany not before 2020...

RE:Growing weed in Germany not before 2020...Nice Find Tims. News not so bad at all. Excerpt fro article: 

Rising demand and delivery bottlenecks 
  "Since March 2017, the health insurance companies have been assuming the costs of medical cannabis for critically ill people under certain conditions. The numbers are increasing from quarter to quarter, it is said at the Federal Pharmacy. There are no official numbers. Estimates vary between 12,000 and 30,000 patients. Thus, the demand is well above the expectations of the Federal Government: The law was introduced in the legal introduction of cannabis as medicine a year ago from almost 700 new patients. To date, demand has been met by imports from the Netherlands and increasingly also from Canada. However, patients and pharmacies have repeatedly complained of delivery bottlenecks in the past. The cultivation in Germany should close this supply gap. "In fact, the patients are the biggest losers of this result," comments Knopp.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities